Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytomegalovirus (CMV) 65 kDa phosphoprotein (pp65), encoded by the UL83 gene, is an abundant tegument protein of human cytomegalovirus (HCMV). It plays a critical role in viral replication and immune evasion by counteracting host antiviral responses, such as inhibiting interferon regulatory factor 3 (IRF3) and cGAS-STING signaling. Because pp65 is highly immunogenic, its peptide epitopes (such as the HLA-A*02:01-restricted NLVPMVATV) are major targets of the host cellular immune response, eliciting robust CD4+ and CD8+ T-cell activation. In clinical therapeutics, these peptide epitopes are targeted to prevent or treat CMV reactivation in immunocompromised individuals, such as transplant recipients, and are also investigated as tumor-associated antigens in cancers like glioblastoma. Therapeutic strategies include peptide-based vaccines (e.g., CMVPepVax, PEP-CMV) that stimulate endogenous T-cell immunity, and adoptive immunotherapies (e.g., TCR-T cells) that utilize pp65-specific T cells to eliminate infected or malignant cells.
Drugs targeting CMV pp65 peptide epitopes act primarily as vaccines or adoptive immunotherapies. Peptide vaccines (such as CMVPepVax and PEP-CMV) deliver these immunodominant epitopes to antigen-presenting cells, which present them on HLA molecules to stimulate and expand endogenous CMV-specific CD4+ and CD8+ T cells. Adoptive cell therapies, including TCR-T cells and CMV-specific cytotoxic T lymphocytes, utilize these epitopes to select, expand, or genetically engineer T cells in vitro, which are then infused into patients to directly target and eliminate CMV-infected cells or tumor cells expressing pp65.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytomegalovirus 65 kDa phosphoprotein (pp65) peptide epitopes (CMV pp65).